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Purpose. To determine the effectiveness of autologous platelet lysate (APL) eye drops in patients with primary Sjo¨gren syndrome
(SS) dry eye, refractory to standard therapy, in comparisonwith patients treated with artificial tears.We focused on the effect of APL
on corneamorphology with the in vivo confocal microscopy (IVCM).Methods. Patients were assigned to two groups: group A used
autologous platelet lysate QID, and group B used preservative-free artificial tears QID, for 90 days. Ophthalmological assessments
included ocular surface disease index (OSDI), best corrected visual acuity (BCVA), Schirmer test, fluorescein score, and breakup
time (BUT). A subgroup of patients in group A underwent IVCM: corneal basal epithelium, subbasal nerves, Langerhans cells,
anterior stroma activated keratocytes, and reflectivity were evaluated. Results. 60 eyes of 30 patients were enrolled; in group A
(𝑛 = 20 patients) mean OSDI, fluorescein score, and BUT showed significant improvement compared with group B (𝑛 = 10
patients). The IVCM showed a significant increase in basal epithelium cells density and subbasal nerve plexus density and number
and a decrease in Langerhans cells density (𝑝 < 0.05). Conclusion. APL was found effective in the treatment of SS dry eye. IVCM
seems to be a useful tool to visualize cornea morphologic modifications.
1. Introduction
Sjo¨gren syndrome (SS) is a chronic multisystem autoim-
mune disease characterized by hypofunction of salivary and
lacrimal glands [1]. The pathogenesis of the dysfunction is
due to a T-lymphocyte mediated destruction of the exocrine
glands [2].
The result of the immune-mediate infiltration of the
lacrimal gland is the development of a severe dry eye
syndrome (DES).
The mainstay of conventional therapy for dry eye is the
application of preservative-free artificial eye drops, which
provide lubrication of the surface of the eye. Based on the
concept that inflammation has a key role in the pathogenesis
of dry eye, different treatment options, such as corticosteroids
and cyclosporine, are used as a second-line treatment inmore
severe dry eye [3, 4].
However, none of the commercially available artificial
tear preparations and anti-inflammatory topical treatment
have the properties of the human tears. They do not contain
growth factors (GFs), such as transforming growth factor
𝛽 (TGF-𝛽), and other components, including vitamin A,
fibronectin, and other cytokines, which are necessary for the
maintenance of normal corneal epithelium [5]. In particular,
GFs stimulate tissue healing by inducing mesenchymal and
epithelial cells migration and proliferation in case of ocular
surface damage [6].
Since some of these components are found in serum, and
its composition is very similar to natural tears, the autologous
serum (AS) has been used since 1984 [7] as a second-line
therapy for dry eye. Nevertheless, its potential benefits have
been questioned by a recent meta-analysis [8].
Platelet alfa granules are a major source of GFs and
are rich in platelet derived growth factor (PDGF), which
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plays an important role in the maintenance of ocular surface
and tear film stability. PDGF promotes the chemotaxis of
fibroblasts, monocytes, and macrophages and stimulates
the expression of TGF-𝛽 that inhibits metalloproteases and
decreases inflammation [9].These findings prompted the use
of platelet rich plasma (PRP), platelet rich plasma in growth
factors (PRGF), and autologous plasma rich in PDGFs eye
drops (PRGD); indeed, recent studies on PRP [10], PRGF [11],
and PRGD [12] have reported an improvement in both the
objective and subjective outcomes in DES patients.
The use of in vivo confocal microscopy (IVCM) offers a
completely new approach in the study of the ocular surface,
with a noninvasive high resolution analysis [13, 14] that allows
both a quantitative histopathological assessment of cornea
damage and a qualitative evaluation of cellular and nerve
properties [15–17].
IVCMhas been used to analyze themorphology of cornea
in DES and to study its relationship with the clinical evalua-
tion.Themorphological abnormalities that appear in patients
with SS were first demonstrated in 2003 by Tuominen et al.
[18] and then confirmed by other authors [19, 20]. A patchy
corneal epithelium, an activation of anterior keratocytes, and
an abnormal subbasal nerve plexus have been described.
Some studies reported that these abnormalities are reversible
by a topical treatment with hemocomponents that are able to
restore epithelial integrity [21, 22].
In this study, we evaluated the efficacy of autologous
platelet lysate (APL) eye drops in patients with primary SS
refractory dry eye in comparison to artificial free preserva-
tives tears. We focused on the histological effect that APL
could have on corneal morphological modifications with a
layer-by- layer analysis of the corneal ultrastructure in a
sample of patients treated with APL.
2. Methods
This prospective case-control study was conducted from July
2014 to May 2015 at the University Eye Clinic of Turin. The
study was conducted in accordance with the Declaration of
Helsinki (1964) and approved by our Ethics Committee.
2.1. Patients Selection. We included patients with a diagnosis
of SS according to the classification criteria of the American-
European Consensus [1], a dry eye severity level ≥2 (Dry Eye
Severity Grading Scheme,Workshop 2007), an ocular surface
disease index (OSDI) ≥23, and a corneal fluorescein staining
score≥1 onOxford scale. All patientswere refractory formore
than 2 months to previous conventional therapy (artificial
tears, steroids, cyclosporine A, or autologous serum).
We excluded patients with ocular infections, previous
corneal surgery (refractive surgery or corneal transplanta-
tion), positive tests for HBV, HCV, HIV, and fever, or sepsis.
Platelet count had to be higher than 100 × 103/𝜇L and Hb
>10 g/dL.
Patients were enrolled and assigned to two groups,
according to the randomization criteria 2 : 1. GroupApatients
were treatedwith eye drops and groupBwith preservative-free
artificial tears (0.2% hyaluronic acid and TS-polysaccharide
0.2%). Both groups were treated for 90 days, 1 drop 4 QID.
Both eyeswere examined in all subjects, and, for statistical
analysis, both eyes were selected if responding to inclusion
criteria and separately analyzed.
2.2. Autologous Platelet Lysate Eye Drops Preparation. The
withdrawal and the APL eye drops preparation were con-
ducted at the Blood Bank, AOU Citta` della Salute e della
Scienza di Torino. A volume of 250 to 350mL of venous
peripheral blood was sampled from each patient, depending
on platelet count, Hb value, total blood volume, and clinical
condition; the autologous packed red blood cells separated
from whole blood could be reinfused in patients having
mild anemia (Hb < 11 g/dL). CompoFlow T & B Fresenius
Kabi bags, containing CPD anticoagulant, were used for the
collection of blood. The blood was left for 60min at room
temperature and then centrifuged at 1580 rpm × 8 minutes
(centrifuge Cryofuge 6000i) to obtain the PRP (platelet rich
plasma) that underwent a second centrifugation (4000 rpm ×
8min). The PPP (platelet poor plasma) supernatant was
partially removed to obtain a platelet concentration of 1.000 ×
103/𝜇L ± 10%. PRP was left at room temperature for 30
minutes, and then it was diluted by addition of 0.9% NaCl
saline solution until a final concentration of 50% and platelets
were lysed by three consecutive thermal shocks. Platelet lysate
(PL)was centrifuged (4000 rpm× 8min) and the supernatant
PL was poured into a collection bag. The bag was connected
to a COL.C30 (BiomedDevice) kit and then aliquoted into 30
sterile vials (following Biomed Device instructions) and kept
frozen at −80∘C. A sample of the final preparation was used
for bacterial culture (BacT/ALERT) that had to be negative
before the delivery to the patient.
Patients were instructed to keep APL frozen, to thaw the
single daily dose the night before, and to store it at 4∘C during
the day.Thirty single doses of platelet lysate were delivered to
group A subjects every 30 days. The schedule of use was two
drops QID for 90 days.
2.3. Ophthalmological Assessment. Before and after 90 days
of therapy, patients underwent an ophthalmologic assessment
comprehensive of subjective symptoms evaluation by ocular
surface disease index (OSDI), Schirmer test type I, breakup
time (BUT), and corneal fluorescein staining (Oxford scale).
Moreover, best corrected visual acuity (BCVA) was evalu-
ated in Snellen lines and eyelid malposition or squamous
metaplasia as well as anterior and posterior blepharitis (Efron
Scale) [23], conjunctival folds (LIPCOF) [24], and Ocular
Protection Index (OPI) were checked. Patients were then
classified according to the Dry Eye Severity Grading Scheme
and only those with grade ≥2 were enrolled in the study.
Patient’s examination was always conducted by the same
observer (AV).
In case of suspected conjunctivitis, the treatment was sus-
pended and a microbial culture was performed to prescribe
an appropriate local therapy, and patients took on again their
original treatment after resolution.
2.4. In Vivo Corneal Confocal Microscopy Assessment. In vivo
confocal microscopy was performed before and after 90 days
of therapy with APL, on a sample of patients (subgroup 2)
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randomized from subjects treated with APL (group A), with
Heidelberg Retina Tomograph (HRT II) in combination with
Rostock Cornea Module (RCM, 63x/0.9W. 670 nm, ∞/0;
Zeiss, Jena, Germany) and CCD camera.
The microscopy was performed on both eyes of each
patient after a topical instillation of anesthetic (0.4% oxybup-
rocaine hydrochloride). A drop of an ophthalmic gel (2.0 g
hydroxypropyl methylcellulose) was applied on the ocular
surface, as coupling medium, to improve the adhesion of the
contact cap objective to the cornea. Proper alignment and
positioning of the head were maintained with the help of a
dedicated target mobile red fixation light for the contralateral
eye.
After the exam, the integrity of the corneal surface was
controlled at the slit lamp and patients were medicated with
antibiotic eye drops (tobramycin ophthalmic solution 0.3%).
We examined the central corneal areas, where images of
intermediate and deep epithelial layers and anterior stroma
were acquired and analyzed.
Patient’s examination was always conducted by the same
observer (TV).
All images were reviewed, and three well-focused micro-
graphs for each corneal scan were manually selected. The
micrographs were assessed in a masked way by one observer;
the mean value of series of three readings was recorded for
each parameter.
Evaluated parameters included the following:
(i) Basal epithelium cell density (cells/mm2): basal
epithelial layer was considered 10𝜇mabove themem-
brane of Bowman. The counting was carried out
within a region of interest of standardized size (region
of interest [ROI] = 100 × 100 𝜇m) using the manual
cell counting system offered with the software. The
system automatically calculated the density by the
function “cell count.”
(ii) Number of subbasal nerve fibers (between Bowman’s
membrane and the basal layer of epithelial, where
nerve fibers run parallel to the corneal surface): it is
defined as the sum of nerve branches in each frame;
images with the greatest number of visible nerve
fibers were chosen for each series of acquisitions.
Only fibers longer than 50𝜇m were considered and
counted as a separated branch.
(iii) Nerve fiber density (𝜇m/160000 𝜇m2): it is defined as
the sum of nerve fibers length (>50𝜇m), considered
in the area of 400 × 400 𝜇m (0.1589mm2, defined
as the widest area possible); it was performed using
the function MEASUREMENTS > J GROUP MEA-
SUREMENTS of NeuronJ, plugin software ImageJ
(available at http://rsb.info.nih.gov/ij/) (Figure 1).
(iv) Activated keratocytes density of the anterior stroma
(number of activated keratocytes/mm2): number of
activated keratocytes in the stroma of the Central
Front is defined as hyperreflective and with cyto-
plasm extensions, 20𝜇m under the Bowman layer.
The counting was carried out using the manual cell
counting system offered with the software in the
Figure 1: An example of neuron tracing with NeuronJ software.The
plugin facilitates the tracing and quantification of nerves.
region of interest (ROI) of 400× 400𝜇m(0.1589mm2,
defined as the widest area possible).
(v) Anterior stroma mean gray value: it is expressed with
a value referred to as gray scale from 0 (black) to
255 (white) in Optical Units (OU), in relation to the
anterior stroma reflectivity, with ImageJ software [25].
(vi) Langerhans cells (LCs) density (LCs/mm2): dendritic
cells number was manually counted in each corneal
section at the level of subbasal nerves, selecting the
images in which there was a greater density of LCs.
The counting was carried out using the manual cell
counting system offered with the software in the
region of interest (ROI) of 400× 400𝜇m(0.1589mm2,
defined as the widest area possible).
2.5. Statistical Analysis. Descriptive statistics were produced
for demographic, clinical, and laboratory variables.Mean and
standard deviation were calculated for quantitative variables
normally distributed;median and IQRwere presented for not
normally distributed quantitative variables and ordinal vari-
ables. Categorical variables were presented with frequencies
and percentages.
A sample size of 50 eyes was calculated to detect a
difference in OSDI between interventions of 50%, defining
significance level of 0.05 and power of 70%.
The Wilcoxon test (𝑘 = 2) was used for quantitative
continuous variables and for ordinal variables in order to
assess statistically significant changes from the baseline. The
nonparametricMann-Whitney𝑈 test was chosen to compare
the continuous quantitative variables and ordinal variables
between the two groups; Fisher’s exact test was used to
compare the nominal categorical variableswhere appropriate.
Performed testswere bilateral and the level of significancewas
set at 5%.The data were analyzed using the statistical software
R.
3. Results
From July 2014 to May 2015, we enrolled 30 patients (mean
age 59.5 ± 12.2 years) with primary Sjo¨gren syndrome
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Table 1: Patients characteristics at baseline. Group A = patients
assigned to APL; group B = patients assigned to artificial tears.
Group A Group B 𝑝 value
Female, 𝑛 (%) 19.0 (95) 10.0 (100.0) 1.00
Age, mean (SD) years 60.4 (11.68) 59.5 (13.34) 0.758
Dry eye, mean (SD) years 7.6 (6.5) 7.5 (6.2) 0.767
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Figure 2: Comparison of OSDI score between patients in group
A (APL) and patients in group B (artificial tears). OSDI score was
significantly lower in group A patients compared with the group B
patients after treatment (𝑝 < 0.05).
(selected from a starting group of 164 patients with primary
SS followed up by the Rheumatology Department, the AOU
Citta` della Salute e della Scienza di Torino, Turin). Group A
consisted of 20 patients (40 eyes) and group B of 10 patients
(20 eyes); demographic characteristics are summarized in
Table 1. Dry eye duration was considered from the diagnosis
of SS. The groups at baseline did not have significant differ-
ences (𝑝 > 0.05).
3.1. Ophthalmological Assessment. The ophthalmological
parameters assessed are reported in Table 2.
None of the subjects presented eyelid abnormalities and
squamous metaplasia.
Mean OSDI score statistically decreased in group A from
60, 56 ± 17, and 69 to 21, 75 ± 9, and 86 after 90 days with APL
therapy (Δ = 38, 82, 𝑝 value = 0.00438). In group B, it slightly
decreased from 60, 67 ± 16, and 19 to 53, 60 ± 14, and 91 (Δ =
7, 07). The differences between the two groups after 90 days
were statistically significant (𝑝 value = 1.007𝑒−05) (Figure 2).
Schirmer test values did not change significantly after 90
days of treatment between the two groups (𝑝 value: 0.544);
however, in group A, there was an increase in BUT value after
treatment, compared to group B (𝑝 value < 0.001) (Figure 3).
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Figure 3: Comparison of BUT values between patients in group
A (APL) and patients in group B (artificial tear). BUT increased
significantly in groupA patients comparedwith the group B patients
after treatment (𝑝 < 0.05).
Concerning the fluorescein score, the differences in the
mean ocular surface staining scores between the two groups
after treatment were statistically significant (𝑝 < 0.05). After
90 days of treatment, 80% of the examined eyes showed an
Oxford score ≤1 (Figure 4).
The OPI value was significantly higher at the end of the
treatment in group A compared to group B (𝑝 < 0.05) and a
significant decrease in the mean values of posterior blephari-
tis (𝑝 < 0.05) was observed in group A compared to group B.
The BCVA significantly increased after 90 days in group
A, but the improvement is not statistically significant in
comparison with the treatment of group B (𝑝 value = 0.100).
3.2. In Vivo Confocal Microscopy. In vivo confocal micros-
copywas performed at baseline and after 90 days of treatment
on 10 patients of group A (20 eyes analyzed); this subgroup
(subgroup 2) was randomized from group A. Excluded
patients are defined as subgroup 1. Table 3 shows that there
are not statistically significant differences between the two
subgroups at baseline.
After treatment, a statistically significant increase in basal
epithelium cells density (𝑝 value = 0.005) was detected;
moreover, an increase in number of subbasal nerve fibers
(𝑝 value = 0.005) as well as an increase in the density of
innervation (𝑝 value = 0.003) was found (Figure 5).
The assessment of gray value of the anterior stroma did
not show any statistically significant changes after 90 days of
treatment (𝑝 value = 0.222), and no differences were found
in activated keratocytes density at the end of the treatment
period (𝑝 value = 0.976).
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Table 2: Ophthalmological assessment.
Group A Group B 𝑝 valueGr. A versus Gr. B
OSDI
𝑇0 Media (SD) 60.56 (17.69) 60.67 (16.19) 0.821
𝑇90 Media (SD) 21.75 (9.86) 53.60 (14.91) <0.001∗
𝑝 value 0.000438∗ 0.059336
Fluorescein score (0–5)
𝑇0 Median (IQR) 2 (2) 3 (2.5) 0.17
𝑇90 Median (IQR) 1 (2) 3 (2) <0.001∗
𝑝 value <0.001∗ 0.463
FBUT (sec)
𝑇0 Median (IQR) 2 (1) 2 (2) 0.18
𝑇90 Median (IQR) 3.5 (2) 2 (1) <0.001∗
𝑝 value 0.005∗ 0.463
BCVA
𝑇0 Median (IQR) 8 (4) 6 (3.5) 0.218
𝑇90 Median (IQR) 8 (3.5) 6 (3.5) 0.100
𝑝 value 0.008∗ 0.317
Schirmer test (mm)
𝑇0 Median (IQR) 3 (2) 3 (2) 0.989
𝑇90 Median (IQR) 3 (1) 3 (0.5) 0.544
𝑝 value 0.0611 0.328065
Anterior blepharitis (grades 0–4)
𝑇0 Median (IQR) 1 (1) 2 (1.5) 0.092
𝑇90 Median (IQR) 1 (0.5) 2 (1.5) 0.778
𝑝 value 0.055 0.109
Posterior blepharitis (grades 0–4)
𝑇0 Median (IQR) 1 (1) 1.5 (1) 0.748
𝑇90 Median (IQR) 1 (1) 1.5 (1.5) 0.036∗
𝑝 value 0.011∗ 0.310
Lipcof (grades 0–3)
𝑇0 Median (IQR) 3 (2) 3 (1) 0.419
𝑇90 Median (IQR) 3 (2) 3 (1) 0.994
𝑝 value 1.000 1.000
OPI (>/<1)
𝑇0 Median (IQR) 0.29 0.23 0.778
𝑇90 Median (IQR) 0.53 0.25 <0.001
𝑝 value <0.001∗ 0.245
𝑇0 = time 0; 𝑇90 = time 90 days; SD = standard deviation; IQR = interquartile range; OSDI = ocular surface disease index; OPI = ocular protection index;
FBUT = breakup time; BCVA = best corrected visual acuity.
∗Statistically significant results.
Table 3: Basal characteristics of subgroup 1 (nonevaluated by IVCM) and subgroup 2 (evaluated by IVCM).
Subgroup 1 Subgroup 2 𝑝 value
Age Media (SD) 63.67 (8.73) 57.6 (11.76) 0.692
Sex Female :male (%) 9 : 10 (90) 10 : 0 (100) 1.000
OSDI Media (SD) 63.73 (21.74) 56.07 (19.3) 0.397
Fluorescein score Median (IQR) 2 (1) 1.5 (1.5) 0.744
BUT Median (IQR) 2 (1.5) 3 (1) 0.287
Schirmer test Median (IQR) 3 (1) 4 (1) 0.055
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Table 4: Confocal microscopy assessments, subgroup 2.
𝑇0 𝑇90 𝑝 value
Basal epithelial cell density (cell/mm2)
Media 5810.52 6680.16 0.005∗
SD 859.78 739.91
Nerve number (𝑛/frame)
Media 5.11 7.72 0.005∗
SD 2.60 3.62
Nerve density (𝜇m/frame)
Median 1070.25 1655.0 0.003∗
IQR 906.46 1631.67
Gray value anterior stroma (OU)
Median 50.33 52.00 0.222
IQR 11 5.65
Activated keratocyte (cell/mm2)
Media 42.04 39.08 0.976
SD 20.72 20.64
Langerhans cells (cell/mm2)
Median 34.50 31.33 0.024∗
IQR 127.33 93.34
∗Statistically significant results.
Finally, a statistically significant decrease of Langerhans
cell density (𝑝 value = 0.024) was detected. These results are
presented in Table 4.
4. Discussion
Although there has been a relevant increase in knowl-
edge regarding pathophysiology and therapeutic strategies
of dry eye, severe dry eye constitutes a major management
challenge. In fact, there is a large cohort of severe dry
eye patients having persistent signs and symptoms despite
maximal conventional therapies.
The critical role of inflammation in the pathogenesis of
dry eye has suggested treatment options other than artificial
tears. Topical administration of corticosteroids has been
reported to improve signs and symptoms in patients with
KCS [26], but these treatments cannot be used as long-term
therapy and need careful monitoring, due to steroid-related
complications (increased intraocular pressure and cataract).
Clinical trials have shown topical cyclosporine to be effective
in patients with moderate to severe dry eye, because of its
ability to decrease inflammation and increase goblet cells
density [27–29]. However, topical cyclosporine is correlated
with several side effects, such as intolerable irritation, limiting
its use [30].
It has been demonstrated that a reduction in epithe-
liotropic factors can lead to a loss of epithelial integrity and a
delay in healing process; since standard therapy for DES such
as artificial tears, corticosteroid, and cyclosporine is not able
to restore the natural composition in GF of human tears, the
use of hemoderivatives has gained popularity.
The autologous serum therapy is worldwide accepted
[31–33], but the practicalities and published evidence were
G
r. 
A
_T
0
G
r. 
A
_T
90
G
r. 
B_
T
0
G
r. 
B_
T
90
Fluorescein staining
0
1
2
3
4
5
Sc
or
e
Figure 4: Comparison of fluorescein score between patients in
group A (APL) and patients in group B (artificial tear). Fluorescein
score was significantly lower in group A patients compared with the
group B patients after treatment (𝑝 < 0.05).
recently reviewed with the evidence that the use of AS was
not associated with effects based on objective measurements.
This result could be due to the presence of a high level of
proinflammatory cytokine in the serum [34].
Based on the concept that platelet 𝛼 granules are a major
source of GFs, the research interest has moved to platelet-
enriched plasma [9, 35]. Vitamin A, Endothelial Growth
Factor (EGF), fibronectin, TGF-𝛽, and nerve growth factor
(NGF) are necessary for maintaining the integrity of con-
junctival and corneal integrity and it has been demonstrated
that LPA is rich in these GFs. A critical role seems to be
played by TGF-𝛽, in relation to the balance T regulatory
(Treg)/Thelper 17 (Th17). TGF-𝛽 is a pleiotropic cytokine
that can have pro- or anti-inflammatory effects depending
on the context. It has been demonstrated that the correct
Treg/Th17 ratio normally contributes to the maintenance of
immune tolerance. Inflammatory interleukins, such as IL-6
or IL-27, can alter the balance in favor of Th17, promoting
the production of interleukin-17 (IL-17) [36]. TGF-𝛽, in
appropriate concentrations, inhibits the priming of Th17,
converting the naive T cell in Treg suppressor [37, 38].
Uncontrolled clinical studies have provided evidence of
symptoms decrease and objective parameters improvement,
such as impression cytology and BUT, after PRP and APL
treatment in different pathologies and with a different posol-
ogy or timing [10–12].
To our knowledge, this is the first randomized prospective
study evaluating the effectiveness of APL. We used the
standardized OSDI survey and objective clinical measures to
evaluate its efficacy. Moreover, for the first time, we assessed
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Figure 5: Confocal images of subbasal nerves, in central corneal sectors. At baseline (a–c), many Langerhans cells can be observed at this
level; after 3-month-long treatment (b–d), a decreased number of inflammatory cells and an increased number of nerves were found. Figures
show the improvement in corneal subbasal nerve plexus for two representative patients treated with APL.
the cornealmorphologicalmodifications after APL treatment
by IVCM.
In our study, subjects without a satisfactory control of the
disease with conventional topical therapy achieved improve-
ment in symptoms after APL treatment. This improvement
was significantly higher compared to patients treated with
tear substitutes.
FBUT average and, in consequence, the mean value of
OPI increased in patients treated with LPA, indicating greater
stability and an improvement in quality of the tear film. The
corneal staining score improved significantly and after 90
days of treatment 80% of patients showed anOxford score ≤1.
BCVAdid not increase significantly comparedwith group
B, but an improvement was found in group A from the base-
line. It must be considered that the decrease in visual acuity
in these patients is probably due to other causes (conditioning
regimen, topical and systemic steroids, and cataract) than tear
film instability and therefore not reversible by platelet lysate.
It has been demonstrated that the visual acuity measured by
Snellen charts is not a good indicator of visual disturbances
in patients suffering from dry eye. The Hartmann-Shack
aberrometry and the double-pass aberrometry with OQAS
(Optical Quality Analysis System) were found to be much
more sensitive in quantifying visual disturbances in these
patients [39].
Regarding side effects, there was only one reported
conjunctivitis case during the treatment with LPA; the patient
was temporarily excluded and resumed in group A after
appropriate antibiotic therapy. The APL has bacteriostatic
factors (𝛽-lysine, lactoferrin, antibodies IgG and IgA, and
lysozyme), whichmake superfluous addition of preservatives;
however, all preparations underwent a bacterial culture
before delivering.
Previous IVCM studies found morphological abnormal-
ities in SS corneas. They described abnormal epithelial and
stromal cells, decreased corneal thickness, and alterations of
nerves number, density, and tortuosity as well as increased
density of LCs [18, 19, 40–42].
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After 3 months of treatment with APL, an increase in cell
density of basal layer was found; such finding may be due
to the migration of stem cells in division [43], attempting to
reepithelize corneal central sectors. We observed complete
resolution of corneal epithelial defect in 40% of treated eyes
and an improvement in 90% of eyes.
The neuronal morphometric analysis of images captured
with IVCMand processedwithNeuronJ showed an increased
number and density of subbasal nerves after 3 months. This
improvement could be due to the direct or indirect action
of nerve growth factor (NGF), present in APL. NGF in a
neurotrophin has a role in nerve sprouting and damaged
neurons restoring. Even if its use has shown encouraging
results in few works that state its efficacy in neurite sprouting
by neural cells [44–46], the chance that the APL could deter-
mine the regeneration of corneal nerves is currently discussed
in literature [47]. A number of authors have recently observed
that autologous serum is effective in restoring nerve topog-
raphy through nerve regeneration in patients with corneal
neuropathy [21, 22]. Our study showed similar results, but
the limited sample and the not comparative nature of the
evaluation do not allow more in-depth analyses on factors
favoring this response. However, the leading mechanism for
the actual nerve regeneration remains to be determined. It is
possible that an improvement in epithelial healing, inflamma-
tory response, and tear film changes could have a main role.
It is widely known that Langerhans cells migration is
influenced by cytokines and chemokines [48] and that a
significant increase of LCs density has been observed in the
subbasal nerve plexus in patients with SS [41]. In group A
patients, the density of Langerhans cells in central areas of
the cornea underwent a significant reduction, suggesting the
anti-inflammatory activity of platelet lysate. In support of
this evidence, it has been shown that TGF-𝛽, in suitable
concentrations, can suppress resident DC maturation [49].
Activated stromal keratocytes density and anterior
stroma gray values (Optical Units), which correspond to
stromal reflectivity, did not change significantly after the
treatment; this finding is probably due to the bioavailability
of platelet lysate at this level, which is not known, but it could
be reasonably expected to be very low (below 5%).
Themain limitation of this study was the absence of eval-
uation of repeatability for confocal microscopy parameters.
In literature, an inter- and intraobserver variance inferior to
5% [25, 50] is reported. Based on this data showing a high
repeatability of IVCM, we decided not to undergo this type
of analysis in our study.
The quantity of blood extraction required for the APL
preparation is clearly higher than the one for AS preparation
[51], in order to obtain the desired platelets concentration.
However, the blood sample collection was conducted in safe
conditions at theTransfusional Center of theCitta` della Salute
e della Scienza by skilled nurses and Hb values were strictly
evaluated before and after the procedure to exclude the
potential risk of anemia.The blood sample was drawn once at
the beginning of the study to increase patient’s comfort and
compliance. The optimal concentration of growth factors in
the APL has not been established yet. The high interpatient
variability of growth factor can potentially be responsible for
differences in the efficacy of this treatment [12]. However, the
preparation of any blood derivate is not standardized and the
concentration of growth factors in any blood derivate is not
completely clear. As a matter of fact, even the AS has been
used in different studies with concentrations ranging from 20
to 100%. The minimal effective concentration of autologous
hemoderivatives is still unknown and further studies should
be addressed to define this value.
5. Conclusions
In conclusion, this study supports the hypothesis that autolo-
gous platelet lysate eye drops are effective on both subjective
symptoms and objective findings, in the treatment of signif-
icant dry eye, in patients with primary Sjo¨gren syndrome.
The IVCM images added objectiveness to the evaluation
suggesting that APL could be effective in restoring corneal
damage by promoting epithelial and nerve regeneration and
decreasing Langerhans cells. Our results encourage the use
of morphological evaluations as a useful tool in the diagnosis
and management of dry eye.
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